Lupin Ltd. Investment Update: Divergent Analyst Perspectives

Executive Summary Lupin Ltd. experienced a 2% decline in early trading on August 27, 2026, following a prominent downgrade. The stock, down approximately 9% YTD, currently presents a complex investment profile characterized by conflicting outlooks from major institutional brokerages. While Citi warns of structural headwinds and margin compression in the US market, Bernstein maintains a strong bullish stance driven by a recent patent litigation victory. Citi’s Bearish Thesis: Margin Compression & Pipeline Risks Citi has downgraded Lupin to ‘Sell,’ cutting its price target by 19% to ₹2,050. The downgrade is rooted in expected deceleration within Lupin's US operations: Revenue Contraction: US sales are projected to decline from ~$1.3 billion in FY26 to $975 million by FY29E. The current pipeline appears insufficient to offset the impending erosion of key high-margin products like gJynarque and gMyrbetriq. Margin Dilution: Consequently, EBITDA margins are forecasted to compress significantly, falling from 30% in Q1FY27 to 20% by FY29E. Execution Risk: While Apixaban may offer temporary earnings support in FY28E, long-term growth drivers (Neulasta Onpro, Etanercept, and Spiriva Respimat) remain unfiled. This severely limits near-term visibility and elevates execution risk. Bernstein’s Bullish Thesis: Kalydeco Litigation Victory In stark contrast, Bernstein reiterates an ‘Outperform’ rating with a ₹2,707 price target, focusing on a critical legal catalyst. Commercial Catalyst: This judgment removes the primary barrier for Lupin’s first-to-file program. The drug, which treats cystic fibrosis, already holds tentative US FDA approval and carries 180 days of lucrative market exclusivity. Financial Impact: Bernstein estimates this product will contribute $20–$30 million in annual sales, adding up to 2.1% to Lupin's current annualized US revenue base.